The FDA has given Thermo Fisher Scientific business BRAHMS 510(k) clearance for expanded use of its procalcitonin-sensitive Kryptor assay as a tool for antibiotic stewardship in intensive care, emergency departments and other hospital units. The assay, which was previously cleared for clinical use, is also intended to facilitate clinicians' decision-making on the initiation of antibiotic therapy for patients with confirmed or suspected lower-respiratory-tract infections.
FDA expands use of Thermo Fisher's BRAHMS PCT assay
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.